Literature DB >> 17331885

Emerging host cell targets for hepatitis C therapy.

Yupeng He1, Wei Duan, Seng-Lai Tan.   

Abstract

Chronic hepatitis C virus (HCV) infection is a major burden on humanity. The current HCV therapy has limited efficacy, and there is pressing need for new and more effective therapies. Host cell factors that are required for HCV infection, replication and/or pathogenesis represent potential therapeutic targets. Of particular interest are cellular receptors that mediate HCV entry, factors that facilitate HCV replication and assembly, and intracellular pathways involving lipid biosynthesis, oxidative stress and innate immune response. A crucial challenge now is to manipulate such cellular targets pharmacologically for chronic HCV treatment, without being limited by side effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17331885     DOI: 10.1016/j.drudis.2007.01.009

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  8 in total

1.  Hepatitis C virus host cell interactions uncovered.

Authors:  Judith M Gottwein; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-07       Impact factor: 11.205

2.  A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.

Authors:  Bambang S Adiwijaya; Eva Herrmann; Brian Hare; Tara Kieffer; Chao Lin; Ann D Kwong; Varun Garg; John C R Randle; Christoph Sarrazin; Stefan Zeuzem; Paul R Caron
Journal:  PLoS Comput Biol       Date:  2010-04-15       Impact factor: 4.475

3.  Hepatitis C virus core-derived peptides inhibit genotype 1b viral genome replication via interaction with DDX3X.

Authors:  Chaomin Sun; Cara T Pager; Guangxiang Luo; Peter Sarnow; Jamie H D Cate
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

4.  Human enterovirus 71 protein interaction network prompts antiviral drug repositioning.

Authors:  Lu Han; Kang Li; Chaozhi Jin; Jian Wang; Qingjun Li; Qiling Zhang; Qiyue Cheng; Jing Yang; Xiaochen Bo; Shengqi Wang
Journal:  Sci Rep       Date:  2017-02-21       Impact factor: 4.379

5.  Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics.

Authors:  Deborah L Diamond; Andrew J Syder; Jon M Jacobs; Christina M Sorensen; Kathie-Anne Walters; Sean C Proll; Jason E McDermott; Marina A Gritsenko; Qibin Zhang; Rui Zhao; Thomas O Metz; David G Camp; Katrina M Waters; Richard D Smith; Charles M Rice; Michael G Katze
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

6.  Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.

Authors:  Xiaoling Puyang; Danielle L Poulin; Joanna E Mathy; Leah J Anderson; Sue Ma; Zheng Fang; Shejin Zhu; Kai Lin; Roger Fujimoto; Teresa Compton; Brigitte Wiedmann
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

7.  Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants.

Authors:  Anna Maisa; Ute Ströher; Hans-Dieter Klenk; Wolfgang Garten; Thomas Strecker
Journal:  PLoS Negl Trop Dis       Date:  2009-06-02

8.  Sulforaphane Suppresses Hepatitis C Virus Replication by Up-Regulating Heme Oxygenase-1 Expression through PI3K/Nrf2 Pathway.

Authors:  Jung-Sheng Yu; Wei-Chun Chen; Chin-Kai Tseng; Chun-Kuang Lin; Yao-Chin Hsu; Yen-Hsu Chen; Jin-Ching Lee
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.